Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of fimasartan 30 mg versus placebo in mild to moderate essential hypertension
KCT0000390Phase 3Not yet recruiting
- Sponsor
- Boryung
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of fimasartan in essential hypertension, sponsored by Boryung. Planned start Mar 2012; status: not yet recruiting.
02
Drugs
fimasartan
03
Conditions
essential hypertension
Beyond the preview
Go deeper on KCT0000390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0000390.